FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

July 31 2018 A class 3 recall for sodium cromoglicate 2% w/v eye drops and Murine Hayfever Relief...

Effect of omega-3 on heart disease is negligible, finds Cochrane review

Effect of omega-3 on heart disease is negligible, finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

BLF highlights decline in stop smoking prescriptions

BLF highlights decline in stop smoking prescriptions

July 18 2018 There has been a 75% decline in stop smoking treatments being prescribed by GPs and...

Welsh National Survey includes OTC medicine purchases for first time

Welsh National Survey includes OTC medicine purchases for first time

June 28 2018 Over half the population in Wales has reported having bought an over the counter...

Recall issued for several own label glycerine and blackcurrant cough syrups

Recall issued for several own label glycerine and blackcurrant cough syrups

June 20 2018 A Class 2 Drug Recall has been issued for 15 batches of own-brand children’s...

  • FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

    FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

    Tuesday, 31 July 2018 15:24
  • Effect of omega-3 on heart disease is negligible, finds Cochrane review

    Effect of omega-3 on heart disease is negligible, finds Cochrane review

    Thursday, 19 July 2018 10:21
  • BLF highlights decline in stop smoking prescriptions

    BLF highlights decline in stop smoking prescriptions

    Wednesday, 18 July 2018 17:32
  • Welsh National Survey includes OTC medicine purchases for first time

    Welsh National Survey includes OTC medicine purchases for first time

    Thursday, 28 June 2018 16:55
  • Recall issued for several own label glycerine and blackcurrant cough syrups

    Recall issued for several own label glycerine and blackcurrant cough syrups

    Wednesday, 20 June 2018 18:29

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a bmj logo cbAugust 25 2017

Using dietary supplements containing anti-oxidants, zinc and copper can help delay progression of macular degeneration and could be a cost-effective approach to eye care.

With the supplements being relatively inexpensive compared to drugs used to treat disorders such as ‘wet’ age-related macular degeneration, the supplements should be available on the NHS, the researchers have also proposed.

The findings are made in the British Journal of Ophthalmology. Researchers from London and the US evaluated the cost-effectiveness of certain supplements in patients with either bilateral intermediate age-related macular degeneration or unilateral neovascular age-related macular degeneration AMD (nAMD). Quality-adjusted life years (QALYs) and healthcare costs were the main outcome measures when compared to no intervention.

There was an improvement in both QALY with supplements and cost savings over the lifetime of the patient. Depending on the type of combination supplement given, they can be “both cost saving and more effective than no supplement use and should therefore be considered in public health policy.”

Reporting on the study, the BMJ Newsroom said two formulations were trialled. “Formulation 1 contained high doses of vitamins C and E, beta carotene, zinc and copper; in formulation 2, beta carotene was replaced with lutein and zeaxanthin, but the other constituents remained the same. Both formulations are commercially available.

“Their analysis showed that both formulations are cost effective for treating patients with early stage ‘wet’ AMD, but they were more cost effective for those with the condition in just one eye.”

Links:
BMJ Newsroom announcement                  
AY Lee et al. ‘Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data’. British Journal of Ophthalmology. August 2017                  

 

OTC News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...